Focus and Scope
JESTM provides high quality tailored contents to stroke investigators. The scope of the journal covers original studies and reviews in experimental stroke and translational medical research. Special emphases are placed on new concepts and methodological improvements in stroke modeling and translational medicine. JESTM encourages authors to submit articles with controversial/provocative ideas and negative results.
Peer Review Process
Each submitted manuscript will be reviewed by 2-3 reviewers. The selection of reviewers depends on the field that the article covers. Authors may suggest up to 4 potential reviewers. The review process usually takes 3-5 weeks.
Final decision for submitted articles
1. The decision of action will be made basing on reviewers’ comments, editors’ literature search, and editor-in-chief’s judgment.
2. Scientific merits: a manuscript describes a novel study that is scientifically coherent, has biological significance, and represents an important unique contribution to its specific field, regardless of the results being positive or negative.
Open Access Policy
Authors grant AESTM/JESTM copyrights of first publication. All contentspublished by AESTM/JESTM are licensed under a Creative Commons Attribution-Noncommercial 3.0 UnportedLicense (CCANL). Under the CCANL, licensors (authors/publisher) retain non-exclusively the copyrights for their work, and allow anyone to download, reuse, reprint, modify, and distribute their work for non-commercial purposes, so long as the original authors and source are cited, no permission is required from the licensors.
Articles published on JESTM are open-access. Submission and publishing on JESTM are all free.
JESTM is indexed at:
Chemical Abstracts Service
Harvester get CITED.
JESTM will apply for indexing at the following databases after having published sufficient amount of articles:
The international standard serial number (ISSN) for Journal of Experimental Stroke_ Translational Medicine is 1939-067X.
All research involving animals must have been approved by the authors’ institutional review board or equivalent committee and that board must be named by the authors.
It is the responsibility of the corresponding author on a manuscript to ensure that all authors are aware of and approve the submission to JESTM of the manuscript, its content, authorship, and order of authorship.
Scientific misconduct is defined by the Office of Research Integrity as “fabrication, falsification, plagiarism, or other practices that seriously deviate from those that are commonly accepted within the academic community for proposing, conducting, or reporting research.” In cases where there is a suspicion or allegation of scientific misconduct or fraudulent research in manuscripts submitted for review, JESTM reserves the right to pass along these manuscripts to the sponsoring or funding institution or other appropriate authority for investigation. Although JESTM recognizes its responsibility to ensure that the suspicion of misconduct has been addressed, we do not ourselves make such determinations.
Authors are asked at submission to declare whether they have any financial, personal,or professional interests that could be construed to have influenced their paper. Reviewers are also asked to declare any interests that might interfere with their objective assessment of a manuscript. Any relevant competing interests of authors must be available to editors and reviewers during the review process and will be stated in published articles.
The use of standardized nomenclature in all fields of science and medicine is an essential step toward the integration and linking of scientific information reported in published literature. We will enforce the use of correct and established nomenclature wherever possible, such as:
We strongly encourage the use of SI units. If you do not use these exclusively, please provide the SI value in parentheses after each value.
Species names should be italicized (e.g., Mus musculus).
Genes, mutations, genotypes, and alleles should be indicated in italics. Use the recommended name by consulting the appropriate genetic nomenclature database, e.g., HUGO. It is sometimes advisable to indicate the synonyms for the gene the first time it appears in the text. Gene prefixes such as those used for oncogenes or cellular localization should be shown in roman.
The Recommended International Non-Proprietary Name (rINN) of drugs should be provided.